Link Between Biochemical, Anthropometric Variables and CD36 in Metabolic Syndrome After a Low-calorie Diet

NCT ID: NCT06881706

Last Updated: 2025-03-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-01

Study Completion Date

2020-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluated the effects of a weight loss diet on biochemical, anthropometric variables, and cluster of differentiation 36 (CD36) levels in 65 patients newly diagnosed with metabolic syndrome (MetS). Participants followed an 8-week medical nutrition therapy (MNT) designed to achieve at least 5% weight loss. Significant changes were observed in some biochemical parameters and blood pressure among those who adhered to the diet. CD36 levels showed correlations with various metabolic and body composition parameters.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research aimed to assess the impact of a weight loss diet on biochemical and anthropometric variables, as well as CD36 levels, in 80 patients newly diagnosed with metabolic syndrome (MetS) who began a weight loss program. The study was completed all of whom were diagnosed with MetS and had applied to the Internal Medicine Outpatient Clinic at Ordu University Training and Research Hospital. At the start of the study, participants were provided with medical nutrition therapy (MNT) tailored to their energy and nutritional needs, as well as their lifestyle, with the goal of achieving at least a 5% weight loss within 8 weeks. Patients were monitored regularly throughout the process.

Before initiating MNT, participants' general characteristics and dietary habits were collected through face-to-face interviews. Additionally, 24-hour dietary recalls and anthropometric measurements were taken both before and at the end of the 8th week. Biochemical data were retrieved from patient records, blood pressure was measured by a physician, and fasting blood samples were collected for CD36 analysis, which were then stored at -80°C until further examination.

By the end of the study, some individuals adhered strictly to the MNT. Statistical differences were observed in some biochemical parameters and blood pressure between those who complied with MNT and those who did not. Correlations were observed between CD36 levels and some variables.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome Weight Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

There are 2 groups in the study. Both groups consist of individuals with newly diagnosed metabolic syndrome. The first group (intervention group) is the group that applied a weight loss diet and achieved weight loss. The second group (control group) is the group that did not apply a diet and did not achieve weight loss.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group

At the beginning of the study, all participants were given a hypocaloric diet to induce weight loss. Individuals who followed the diet and lost at least 5% of their starting weight constituted this group.

Group Type EXPERIMENTAL

medical nutrition therapy

Intervention Type OTHER

Medical nutrition treatment was planned for all participants with metabolic syndrome. A diet plan was created considering age, gender, blood findings and nutritional habits. Individuals with MetS were given a weight loss diet planned at the basal energy level calculated with the Harris-Benedict equation and applied for 8 weeks. Individuals who applied the weight loss diet were targeted to lose at least 5% of their initial weight at the end of 8 weeks. Individuals who strictly followed the given medical nutrition treatment and achieved the targeted weight loss formed the intervention group, and individuals who did not follow the medical nutrition treatment formed the control group. At the end of the 8 weeks, all parameters, blood pressure and anthropometric measurements of all individuals who participated in the study and retrospective 24-hour food consumption records were recorded again and the study was concluded.

Control Group

At the beginning of the study, all participants were given a hypocaloric diet to induce weight loss. Individuals who did not follow the diet and did not lose at least 5% of their starting weight constituted this group.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

medical nutrition therapy

Medical nutrition treatment was planned for all participants with metabolic syndrome. A diet plan was created considering age, gender, blood findings and nutritional habits. Individuals with MetS were given a weight loss diet planned at the basal energy level calculated with the Harris-Benedict equation and applied for 8 weeks. Individuals who applied the weight loss diet were targeted to lose at least 5% of their initial weight at the end of 8 weeks. Individuals who strictly followed the given medical nutrition treatment and achieved the targeted weight loss formed the intervention group, and individuals who did not follow the medical nutrition treatment formed the control group. At the end of the 8 weeks, all parameters, blood pressure and anthropometric measurements of all individuals who participated in the study and retrospective 24-hour food consumption records were recorded again and the study was concluded.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

hypocaloric diet intervention weight loss intervention

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Being between the ages of 19-64
* Being diagnosed with MetS by a physician according to the International Diabetes Federation (IDF)-2005 metabolic syndrome diagnostic criteria
* Being a volunteer to participate in the study

Exclusion Criteria

* Being pregnant and breastfeeding
* Smoking and drinking alcohol
* Having any chronic disease other than metabolic syndrome
* Taking regular medication
* Taking regular nutritional supplements
* Having a change in weight within the last 3 months
Minimum Eligible Age

19 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ordu University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Duygu MATARACI DEĞİRMENCİ

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mehmet FISUNOGLU, Assoc. Prof.

Role: STUDY_DIRECTOR

Hacettepe University

Ozlem Ozdemir, Assist. Prof

Role: STUDY_CHAIR

Ordu University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ordu University

Ordu, Altınordu, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Khaleel AA, Al-Barzinji RMGT. Soluble CD36 Concentration in Diabetic Hypertensive Patients with Coronary Atherosclerosis. Cell Mol Biol (Noisy-le-grand). 2022 May 22;68(1):109-116. doi: 10.14715/cmb/2022.68.1.14.

Reference Type RESULT
PMID: 35809322 (View on PubMed)

Rac ME, Safranow K, Garanty-Bogacka B, Dziedziejko V, Kurzawski G, Goschorska M, Kuligowska A, Pauli N, Chlubek D. CD36 gene polymorphism and plasma sCD36 as the risk factor in higher cholesterolemia. Arch Pediatr. 2018 Apr;25(3):177-181. doi: 10.1016/j.arcped.2018.01.008. Epub 2018 Mar 23.

Reference Type RESULT
PMID: 29576254 (View on PubMed)

Blomquist C, Chorell E, Ryberg M, Mellberg C, Worrsjo E, Makoveichuk E, Larsson C, Lindahl B, Olivecrona G, Olsson T. Decreased lipogenesis-promoting factors in adipose tissue in postmenopausal women with overweight on a Paleolithic-type diet. Eur J Nutr. 2018 Dec;57(8):2877-2886. doi: 10.1007/s00394-017-1558-0. Epub 2017 Oct 26.

Reference Type RESULT
PMID: 29075849 (View on PubMed)

do Amaral CL, Milagro FI, Curi R, Martinez JA. DNA methylation pattern in overweight women under an energy-restricted diet supplemented with fish oil. Biomed Res Int. 2014;2014:675021. doi: 10.1155/2014/675021. Epub 2014 Jan 22.

Reference Type RESULT
PMID: 24579084 (View on PubMed)

Mora-Rodriguez R, Ortega JF, Morales-Palomo F, Ramirez-Jimenez M. Weight loss but not gains in cardiorespiratory fitness after exercise-training predicts improved health risk factors in metabolic syndrome. Nutr Metab Cardiovasc Dis. 2018 Dec;28(12):1267-1274. doi: 10.1016/j.numecd.2018.08.004. Epub 2018 Aug 23.

Reference Type RESULT
PMID: 30459053 (View on PubMed)

Alkhatatbeh MJ, Ayoub NM, Mhaidat NM, Saadeh NA, Lincz LF. Soluble cluster of differentiation 36 concentrations are not associated with cardiovascular risk factors in middle-aged subjects. Biomed Rep. 2016 May;4(5):642-648. doi: 10.3892/br.2016.622. Epub 2016 Mar 3.

Reference Type RESULT
PMID: 27123261 (View on PubMed)

Yanai H, Chiba H, Morimoto M, Jamieson GA, Matsuno K. Type I CD36 deficiency in humans is not associated with insulin resistance syndrome. Thromb Haemost. 2000 May;83(5):786. No abstract available.

Reference Type RESULT
PMID: 10823279 (View on PubMed)

Furuhashi M, Ura N, Nakata T, Shimamoto K. Insulin sensitivity and lipid metabolism in human CD36 deficiency. Diabetes Care. 2003 Feb;26(2):471-4. doi: 10.2337/diacare.26.2.471.

Reference Type RESULT
PMID: 12547883 (View on PubMed)

Lopez-Carmona MD, Plaza-Seron MC, Vargas-Candela A, Tinahones FJ, Gomez-Huelgas R, Bernal-Lopez MR. CD36 overexpression: a possible etiopathogenic mechanism of atherosclerosis in patients with prediabetes and diabetes. Diabetol Metab Syndr. 2017 Jul 18;9:55. doi: 10.1186/s13098-017-0253-x. eCollection 2017.

Reference Type RESULT
PMID: 28729885 (View on PubMed)

Griffin E, Re A, Hamel N, Fu C, Bush H, McCaffrey T, Asch AS. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nat Med. 2001 Jul;7(7):840-6. doi: 10.1038/89969.

Reference Type RESULT
PMID: 11433350 (View on PubMed)

Marechal L, Laviolette M, Rodrigue-Way A, Sow B, Brochu M, Caron V, Tremblay A. The CD36-PPARgamma Pathway in Metabolic Disorders. Int J Mol Sci. 2018 May 21;19(5):1529. doi: 10.3390/ijms19051529.

Reference Type RESULT
PMID: 29883404 (View on PubMed)

Pardina E, Ferrer R, Rossell J, Ricart-Jane D, Mendez-Lara KA, Baena-Fustegueras JA, Lecube A, Julve J, Peinado-Onsurbe J. Hepatic CD36 downregulation parallels steatosis improvement in morbidly obese undergoing bariatric surgery. Int J Obes (Lond). 2017 Sep;41(9):1388-1393. doi: 10.1038/ijo.2017.115. Epub 2017 May 10.

Reference Type RESULT
PMID: 28555086 (View on PubMed)

Botha J, Nielsen MH, Christensen MH, Vestergaard H, Handberg A. Bariatric surgery reduces CD36-bearing microvesicles of endothelial and monocyte origin. Nutr Metab (Lond). 2018 Oct 23;15:76. doi: 10.1186/s12986-018-0309-4. eCollection 2018.

Reference Type RESULT
PMID: 30386406 (View on PubMed)

Knosgaard L, Kazankov K, Birkebaek NH, Holland-Fischer P, Lange A, Solvig J, Horlyck A, Kristensen K, Rittig S, Vilstrup H, Gronbaek H, Handberg A. Reduced sCD36 following weight loss corresponds to improved insulin sensitivity, dyslipidemia and liver fat in obese children. Eur J Clin Nutr. 2016 Sep;70(9):1073-7. doi: 10.1038/ejcn.2016.88. Epub 2016 Jun 8.

Reference Type RESULT
PMID: 27273071 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Metabolic syndrome and CD36

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effectiveness of MD on MetS Patients
NCT06961682 NOT_YET_RECRUITING NA